Advancing Myocardial Infarction Management: Guideline Adherence, Diagnostic Innovations, and Long-term Outcome Optimization

Saleh Obaid Abdullah Alghadeer [1], Nezar Mohammad Mutlaq Alshammari [1], Hassan Mashe Noman Alshammari [1], Shaiem Halul Swilem Al-Enazi, Nuha Sameer Al Anizi [1], Enas Salem Alruwaili [1], Hamdan Ali Al Alyani [1], Abdulelah Mohammed Mubashir Alamri [1], Wejdan Amein Abdullah [1], Zaina Zaki Almohammed 1, Reham Mohammad Alsoulaimi [1], Salman Fahad Ali Aldubayyan [1], Suhoud Saud Alotaibi [1], Abdullah Abdulrahman Alkhamees [1], Motaeb Nasser Faihan Alotaibi [1], Ahmed Abdulkarim Sulaiman Alnughaymishi [1*]

Abstract

Background: The accurate diagnosis and effective management of myocardial infarction (MI) are pivotal in reducing morbidity and mortality globally. Despite advancements in diagnostic criteria, guideline adherence, and therapeutic strategies, significant challenges remain in understanding short-term and long-term complications. Key initiatives, such as the Third and Fourth Universal Definitions of MI and cardiovascular disease statistics, have contributed valuable insights into the epidemiology, pathophysiology, and management of MI. Methods: This review synthesizes findings from recent studies, including cohort analyses and systematic reviews, addressing MI diagnostics and treatment. Special attention is given to guideline adherence, risk factor evaluation, and the evolving role of advanced imaging techniques like computed tomography angiography. The data were sourced from peer-reviewed journals and professional guidelines, including contributions from the European Society of Cardiology and the American Heart Association. Results: Adherence to statin therapy and other guidelines significantly reduced cardiac complications post-surgery. The role of high-sensitivity biomarkers and imaging in early diagnosis has improved clinical outcomes. However, gaps persist in applying universal definitions and risk scores, particularly in patients with atypical presentations. Studies underscore the importance of integrating psychosocial factors and comorbidities into risk assessments. Innovative diagnostic tools, such as Sgarbossa criteria and TIMI risk scores, continue to enhance predictive accuracy but require further validation in diverse populations. Conclusion: This review highlights the critical importance of standardizing diagnostic criteria, promoting guideline adherence, and leveraging advanced diagnostic modalities to improve MI management. Future research should focus on addressing disparities in healthcare access, optimizing personalized interventions, and evaluating long-term outcomes of current therapeutic strategies. Collaborative efforts between clinicians, researchers, and policymakers are essential to reducing the global burden of MI and improving patient outcomes.

Keywords: Myocardial Infarction, Guideline Adherence, Diagnostic Advances, Risk Stratification, Cardiovascular Outcomes

Significance | Standardizing myocardial infarction definitions, improving guideline adherence, and leveraging diagnostics enhance patient outcomes, addressing global cardiovascular disease challenges.

*Correspondence. Ahmed Abdulkarim Sulaiman Alnughaymishi
Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia
E-mail: ahmad-1577@hotmail.com

Editor Md Shamsuddin sultan khan And accepted by the Editorial Board January 15, 2024 (received for review November 19, 2023)

Introduction

Acute coronary syndrome (ACS) encompasses a spectrum of

Author Affiliation.
[1] Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia

Please Cite This:
Alghadeer, S. O. A., Alshammari, N. M. M., Alshammari, H. M. N., Al-Enazi, &. H. S., Anizi, N. S. A., Alruwaili, &. S., Alyani, &. A. A., Alamri, &. M. M., Abdullah, W. A., Almohammed, Z. Z., Alsoulaimi, R. M., Aldubayyan, S. F. A., Alotaibi, S. S., Alkhamees, A. A., Alotaibi, M. N. F., Alnughaymishi, A. A. S. (2024). "Advancing Myocardial Infarction Management: Guideline Adherence, Diagnostic Innovations, and Long-term Outcome Optimization", Journal of Angiotherapy, 8(1),1-12,10095

clinical conditions marked by a sudden decrease in myocardial perfusion, including ST-segment elevation myocardial infarction (STEMI) (Figure 2), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. It is a global health issue, with over 7 million cases of ACS diagnosed annually worldwide, more than 1 million of which require hospitalization in the United States alone each year (Bhatt, Lopes, & Harrington, 2022). Among these, STEMI is characterized by the complete occlusion of a coronary artery and is responsible for approximately 30% of all ACS cases (Alpert et al., 2000). The hallmark of STEMI is transmural myocardial ischemia, which results in myocardial injury or necrosis (Thygesen et al., 2019). According to the 2018 clinical criteria for myocardial infarction, confirmation of ischemic myocardial injury is established through abnormal cardiac biomarker levels (Thygesen et al., 2019). STEMI is clinically defined by the combination of chest pain, electrocardiogram (ECG) changes, and myocardial ischemia (Bhatt et al., 2022).

Immediate reperfusion therapy is critical in STEMI management. Primary percutaneous coronary intervention (PCI) within 120 minutes of symptom onset is the preferred treatment, reducing mortality from 9% to 7% (Thygesen et al., 2019). However, when PCI is not feasible within this critical time window, fibrinolytic therapy using alteplase, reteplase, or tenecteplase is recommended for patients under 75 years old, with age-adjusted doses for those 75 and older (Bhatt et al., 2022). Streptokinase may also be considered as a cost-effective alternative, particularly in resource-limited settings. Following fibrinolytic therapy, it is essential that patients are transferred to a PCI-capable facility within 24 hours to optimize outcomes (Thygesen et al., 2019).

Myocardial infarction is classified into five types based on underlying etiology, with type 1 being the result of coronary atherothrombosis and type 2 arising from an imbalance between myocardial oxygen supply and demand (Hartikainen et al., 2020). While type 1 and type 2 infarctions often present as NSTEMI, some cases manifest as STEMI (Cohen & Visveswaran, 2020). The pathophysiology of STEMI involves the rupture or erosion of an atherosclerotic plaque, which triggers platelet aggregation and thrombus formation, leading to complete coronary artery occlusion and subsequent myocardial injury (Kolodgie et al., 2001). Risk factors for STEMI include dyslipidemia, diabetes, hypertension, smoking, and a family history of coronary artery disease (Wilson, 1994; Canto et al., 2011).

Cardiovascular disease (CVD), with ACS being a significant contributor, remains the leading cause of morbidity and mortality globally, particularly in low- and middle-income countries (Timmis et al., 2022). In 2019, nearly 5.8 million new cases of ischemic heart disease were reported in the European Society of Cardiology member countries, and CVD was responsible for over 4 million deaths (Timmis et al., 2022). In the United States, approximately 550,000 new and 200,000 recurrent cases of myocardial infarction are diagnosed each year, with a significant proportion requiring hospitalization and intervention (Writing Group Members et al., 2016). STEMI represents about 38% of ACS presentations in the U.S. (Writing Group Members et al., 2016).

The pathophysiology of STEMI involves thrombotic occlusion of a coronary artery, often exacerbated by atherosclerosis and vulnerable plaque rupture (Kolodgie et al., 2001). This occlusion leads to the characteristic "wave-front" pattern of myocardial injury, beginning in the subendocardial layers and progressing to transmural infarction (Bhatt et al., 2022). The resulting ischemia compromises tissue perfusion and may cause significant microvascular dysfunction, further exacerbating myocardial injury (Kolodgie et al., 2001). The complexity of STEMI pathophysiology highlights the critical need for early detection and timely therapeutic intervention to minimize irreversible myocardial damage.

2. Etiology

Myocardial infarction (MI) can be classified into five types (1-5) based on the underlying etiology and pathogenesis, with advancements in cardiovascular imaging, revised electrocardiogram (ECG) criteria, and high-sensitivity cardiovascular biomarker assays facilitating more accurate classifications (Hartikainen et al., 2020). Type 1 MI, primarily caused by intracoronary atherothrombosis, is distinct from types 2 to 5, which may involve other mechanisms, some of which have an atherosclerotic component. Type 2 MI is characterized by an imbalance between myocardial oxygen supply and demand, independent of acute coronary atherothrombosis. While types 1 and 2 are typically spontaneous, types 4 and 5 are related to medical procedures. Type 3 is diagnosed postmortem (Alpert et al., 2000; Thygesen et al., 2018). Most cases of type 1 and 2 MI present as non-ST-segment elevation myocardial infarction (NSTEMI), although some may manifest as ST-segment elevation myocardial infarction (STEMI) (Cohen & Visveswaran, 2020). STEMI occurs due to the obstruction of one or more coronary arteries, usually due to plaque rupture, erosion, fissuring, or dissection, often with the formation of an obstructive thrombus. Primary risk factors for STEMI include dyslipidemia, diabetes, hypertension, smoking, and a family history of coronary artery disease (Wilson, 1994; Canto et al., 2011).

3. Epidemiology

Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity globally, with a disproportionate burden on low- and middle-income countries. Acute coronary syndrome (ACS) frequently presents as the initial manifestation of CVD. In 2019, there were approximately 5.8 million new cases of ischemic heart disease reported across 57 member countries of the European Society of Cardiology (ESC), with a median age-standardized incidence rate of 293.3 per 100,000 individuals (Timmis et al., 2022). CVD remains the leading cause of death in ESC countries, accounting for nearly 2.2 million deaths among women and over 1.9 million deaths among men. Ischemic heart disease is responsible for 38% of deaths in women and 44% in men (Timmis et al., 2022). In the United States, the estimated annual incidence of MI includes 550,000 new cases and 200,000 recurrent cases, with 116,793 fatalities in 2013, 57% of which occurred in men and 43% in women (Writing Group Members et al., 2016). The average age for a first MI is 65.1 years for men and 72 years for women, with 38% of patients presenting with STEMI (Mozaffarian et al., 2016).

4. Pathophysiology

The pathophysiology of acute coronary syndrome (ACS), particularly STEMI, is primarily driven by the complete and sustained occlusion of coronary blood flow, often due to thrombotic events. Coronary atherosclerosis, particularly in the presence of high-risk thin-cap fibroatheromas, can precipitate plaque rupture. This rupture results in endothelial injury, initiating a cascade of platelet adhesion, activation, and aggregation, culminating in thrombosis (Kolodgie et al., 2001; Scharf, 2018). The occlusion leads to a "wave-front" pattern of myocardial injury, progressing from subendocardial to subepicardial layers, ultimately causing transmural myocardial infarction, reflected by ST-segment elevation on the ECG (Reimer & Jennings, 1979). This disruption of blood flow results in myocardial ischemia, which can cause immediate myocardial damage and necessitates urgent medical intervention. Acute ischemia, especially when sudden, can induce significant microvascular dysfunction, further compromising tissue perfusion and exacerbating myocardial injury (Scharf, 2018).

6. History and Physical Examination

The most common symptom prompting healthcare professionals to suspect ACS is acute chest discomfort, which patients may describe as pain, pressure, tightness, heaviness, or burning (Amsterdam et al., 2014). Misdiagnosis or delays may occur due to incomplete patient history or unclear symptom description. Therefore, a thorough medical history and effective communication are crucial for accurate and timely diagnosis. A focused history should include risk factors, presenting symptoms, and recent medication use (Torpy et al., 2009). A complete physical examination should assess vital signs, including blood pressure in both arms, pulse, heart and lung sounds, and signs of heart failure or circulatory compromise (Amsterdam et al., 2014). Notable risk factors for STEMI include age, gender, family history of coronary artery disease, smoking, dyslipidemia, diabetes, hypertension, and abdominal obesity (Canto et al., 2011; Torpy et al., 2009). Cocaine use is a significant risk factor for STEMI, irrespective of other conditions (McCord et al., 2008). Identifying congenital abnormalities, such as familial hypercholesterolemia, may be useful in evaluation, as this condition increases the risk of early-onset atherosclerotic disease and is associated with both STEMI and NSTEMI (Glarner et al., 2023).

7. Evaluation of Diagnostic Modalities for Acute Coronary Syndrome (ACS)

The evaluation of patients suspected of having acute coronary syndrome (ACS) is pivotal for determining appropriate treatment and management strategies. Timely diagnosis of ACS, which encompasses conditions such as ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome (NSTE-ACS), can significantly impact patient outcomes. The use of diagnostic tools such as electrocardiogram (ECG), cardiac biomarkers, transthoracic echocardiogram (TTE), and computed tomography (CT) plays a crucial role in the early detection and management of ACS. This review evaluates the role of these modalities in ACS diagnosis, emphasizing the importance of rapid identification of ischemic events and effective therapeutic interventions.

7.1 Electrocardiogram (ECG)

The resting 12-lead electrocardiogram (ECG) remains the primary diagnostic tool for ACS, particularly in patients presenting with chest pain or similar symptoms. Immediate ECG acquisition upon initial medical contact, followed by interpretation by a qualified healthcare provider within 10 minutes, is essential for guiding management (Thygesen et al., 2018). Initial ECG findings help stratify patients into diagnostic categories based on the presence or absence of ST-segment elevation.

Patients exhibiting acute chest pain with persistent ST-segment elevation are classified as having STEMI, while those without ST-segment elevation are diagnosed with NSTE-ACS (Alpert et al., 2000). The presence of ST-segment elevation, which exceeds 0.1 mV in most leads, is a hallmark of STEMI (Thygesen et al., 2012). For leads V2 and V3, higher thresholds are applied, with the specific cutoffs depending on patient demographics such as age and sex (Ibanez et al., 2018).

In the context of left bundle branch block (LBBB), interpreting ECG results presents unique challenges due to the characteristic changes in the ST segment. The Sgarbossa criteria have been developed to improve the detection of myocardial infarction in patients with LBBB. These criteria focus on ST-segment changes that are concordant or discordant with the QRS complex (Sgarbossa et al., 1996). Despite its high specificity, the Sgarbossa criteria's sensitivity remains a limitation in some cases (Khawaja et al., 2021). Therefore, additional diagnostic modalities may be needed when LBBB is present.

7.2 Cardiac Biomarkers

Cardiac biomarkers are indispensable in the diagnosis and risk stratification of ACS. High-sensitivity cardiac troponin (hs-cTn) is the biomarker of choice for diagnosing myocardial infarction (MI), as it offers superior sensitivity and diagnostic accuracy (Thygesen et al., 2018). According to the fourth universal definition of myocardial infarction, an elevation in hs-cTn levels above the 99th percentile of the healthy population, coupled with clinical signs of myocardial ischemia, confirms the diagnosis of MI (Thygesen et al., 2019). Serial measurements of hs-cTn help in detecting ongoing myocardial injury and guiding therapeutic decisions, with the 0-hour/1-hour algorithm being the preferred method for early risk stratification (Anand et al., 2021).

In cases where STEMI and high-risk NSTE-ACS are ruled out, hs-cTn levels provide critical insights into the severity of myocardial damage and the potential for adverse outcomes (Wildi et al., 2019). The use of hs-cTn in the emergency department setting has been shown to reduce diagnostic uncertainty, shorten hospital stays, and lower healthcare costs (Boeddinghaus et al., 2019). However, it is important to note that biomarker levels must be interpreted in conjunction with clinical presentation and other diagnostic findings.

7.3 Transthoracic Echocardiogram (TTE)

Transthoracic echocardiography (TTE) is a non-invasive imaging modality that can aid in assessing the functional status of the heart, particularly in patients with suspected ACS. While TTE is not routinely used for the diagnosis of ACS, it can be valuable in detecting signs of ongoing ischemia or prior myocardial infarction, such as wall motion abnormalities (Reimer & Jennings, 1979). Furthermore, TTE can help identify alternative causes of chest pain, including acute aortic syndrome or pulmonary embolism, which may present similarly to ACS (Glarner et al., 2023).

However, it is crucial that TTE not delay the transfer of patients with suspected acute coronary artery occlusion to the cardiac catheterization laboratory, where invasive coronary angiography remains the gold standard for assessing coronary artery disease (Canto et al., 2011). In addition, TTE may be particularly useful in patients with concurrent heart failure or other structural heart abnormalities, providing further diagnostic clarity.

7.4 Computed Tomography (CT)

Computed tomography (CT) is an essential tool in the differential diagnosis of chest pain. While CT is not typically used for diagnosing ACS, it can be instrumental in excluding other life-threatening conditions that may present similarly, such as pulmonary embolism or aortic dissection. ECG-gated contrast-enhanced CT angiography of the thoracic aorta and proximal head and neck vessels is recommended in such cases to assess for these conditions (Akbar et al., 2020). However, CT is not recommended as a routine diagnostic tool for patients suspected of having ongoing coronary artery occlusion, as coronary angiography remains the preferred method for assessing the coronary vasculature (Kolodgie et al., 2001).

In patients with unclear diagnoses or inconclusive ECG and biomarker results, CT may provide additional insight into the presence of non-ACS etiologies of chest pain. This approach has proven beneficial in ruling out conditions such as coronary artery anomalies and aortic pathologies that may mimic ACS (Torpy et al., 2009).

The timely and accurate evaluation of ACS requires a multifaceted approach, incorporating ECG, cardiac biomarkers, echocardiography, and CT imaging. Each diagnostic tool offers unique benefits in the early detection and management of ACS, with ECG serving as the cornerstone for initial assessment. Cardiac biomarkers, particularly hs-cTn, provide valuable information regarding myocardial injury and risk stratification. Transthoracic echocardiography and computed tomography offer additional diagnostic support, particularly in cases with diagnostic ambiguity or alternative causes of chest pain. A comprehensive diagnostic strategy that combines these modalities is essential for ensuring optimal outcomes in patients with suspected ACS.

8. Treatment and Management of Acute ST-Elevation Myocardial Infarction (STEMI)

Upon diagnosis of acute STEMI (ST-elevation myocardial infarction), prompt intervention is crucial for optimizing patient outcomes. The cornerstone of management begins with securing intravenous (IV) access and initiating cardiac monitoring to assess the patient's hemodynamic status and to detect arrhythmias. Swift delivery of treatment is paramount, as clinical outcomes heavily depend on several factors including ischemic duration, initial management delays, and reperfusion strategies. Effective care systems can be assessed by the timeliness of treatment in patients suspected of having STEMI, with reperfusion therapy being the focus of early management.

8.1 Oxygen Therapy and Reperfusion Strategies

Oxygen therapy has been traditionally used in STEMI patients, especially in those exhibiting hypoxemia. Recent studies, however, have raised concerns about its use in normoxic patients, with evidence suggesting potential harm (Stub et al., 2015; Hofmann et al., 2017). In patients with normal oxygen saturation, the routine use of oxygen therapy may increase oxidative stress, possibly exacerbating myocardial injury. Therefore, oxygen therapy should only be administered in patients showing hypoxemia or those at risk for it (Stub et al., 2015).

Reperfusion therapy is the most critical intervention in STEMI and should be initiated without delay. Primary percutaneous coronary intervention (PCI) remains the preferred strategy for reperfusion, and it should be performed within 90 minutes of patient arrival at a PCI-capable hospital. If transfer to a PCI-capable center is necessary, the procedure should be conducted within 120 minutes of initial medical contact (O'Gara et al., 2013). In situations where PCI cannot be performed within this timeframe, fibrinolytic therapy should be considered. Fibrinolysis should be administered within 30 minutes of hospital arrival if PCI is not an immediate option (O'Gara et al., 2013).

Following fibrinolysis, patients should be transferred to a PCI center for angiographic evaluation and possible rescue PCI if needed. In cases where fibrinolysis fails, as indicated by the persistence of ST-segment elevation or recurrent chest pain, urgent angiography and rescue PCI are required (Arbel et al., 2018). Even if fibrinolysis appears successful, it is recommended to perform early angiography within 2 to 24 hours (Gershlick et al., 2005).

8.2 Manual Thrombus Aspiration

Thrombus aspiration (TAP) has been considered an adjunctive strategy in PCI for STEMI patients to reduce microvascular obstruction. The TAPAS trial initially suggested that thrombus aspiration might improve clinical outcomes by reducing the thrombus burden and enhancing reperfusion (de Waha et al., 2017). However, subsequent studies have raised doubts about its efficacy and safety. Meta-analyses have shown no significant improvement in clinical outcomes, and concerns regarding an increased risk of stroke in patients undergoing thrombus aspiration have led to a change in practice guidelines. As a result, the 2023 European Society of Cardiology (ESC) guidelines no longer recommend routine thrombus aspiration during PCI in STEMI patients, although it may be considered in patients with high thrombotic burden following PCI (Vlaar et al., 2008; Lagerqvist et al., 2014).

8.3 Pharmacological Therapy

Several pharmacological agents play a critical role in the management of STEMI. Nitroglycerin is used to alleviate anginal pain by inducing coronary vasodilation. However, its use is contraindicated in patients who have taken phosphodiesterase inhibitors in the past 24 hours or in those with right ventricular infarction (Meine et al., 2005). Morphine can be administered for pain relief if nitroglycerin fails to alleviate symptoms, although caution is warranted due to potential adverse effects on outcomes (Meine et al., 2005).

All STEMI patients should receive dual antiplatelet therapy (DAPT) comprising aspirin and a potent P2Y12 inhibitor. The initial dose of aspirin should be administered as early as possible, followed by a maintenance dose of 75-100 mg daily (Jones et al., 2021). P2Y12 inhibitors, such as prasugrel or ticagrelor, have demonstrated superior efficacy compared to clopidogrel in patients undergoing PCI (Wiviott et al., 2007). Clopidogrel should be reserved for cases where prasugrel or ticagrelor are contraindicated or unavailable, or in patients with a high bleeding risk (Gimbel et al., 2020). The choice of P2Y12 inhibitor depends on whether the patient undergoes PCI or fibrinolysis. For patients receiving fibrinolytic therapy, clopidogrel is preferred (Sabatine et al., 2005). The use of P2Y12 inhibitors requires careful consideration of contraindications. For example, prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke (Wiviott et al., 2007).

In addition to antiplatelet therapy, anticoagulation is an essential component of STEMI management. Heparin, low-molecular-weight heparin, bivalirudin, or fondaparinux may be used to prevent further thrombus formation (Braun & Kassop, 2020). Statin therapy is also vital in STEMI patients, as it helps lower low-density lipoprotein cholesterol (LDL-C) levels and improves long-term prognosis. High-intensity statins, such as atorvastatin or rosuvastatin, should be started early, ideally before PCI, to achieve the target LDL-C levels (Mach et al., 2020).

8.4 β-blockers, ACE Inhibitors, and SGLT2 Inhibitors

β-blockers have been shown to reduce mortality in STEMI patients, especially in those with reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (Aarvik et al., 2019). However, their benefits in patients with LVEF greater than 40% following uncomplicated STEMI remain less well-defined (Dahl Aarvik et al., 2019). The CAPRICORN trial demonstrated the efficacy of carvedilol in reducing mortality in patients with reduced LVEF after STEMI (Dargie, 2001).

Angiotensin-converting enzyme (ACE) inhibitors have proven benefits in reducing mortality and preventing heart failure in STEMI patients with LVEF ≤40%, diabetes, chronic kidney disease, or hypertension (Yusuf et al., 2000). ACE inhibitors should be started early in the course of treatment, especially in patients at high risk for adverse outcomes (ACE Inhibitor Myocardial Infarction Collaborative Group, 1998).

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are emerging as beneficial adjuncts in managing STEMI, particularly in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Drugs such as empagliflozin and dapagliflozin have shown promise in improving glycemic control, reducing weight, and lowering blood pressure, without inducing hypoglycemia (Cowie & Fisher, 2020). Recent trials have highlighted their cardiovascular benefits in this patient population (Cowie & Fisher, 2020; Braun et al., 2020).

The management of STEMI requires a comprehensive approach, including prompt reperfusion therapy, pharmacological management, and careful monitoring for complications. Adherence to evidence-based guidelines can significantly improve outcomes for STEMI patients, and new therapeutic options, such as SGLT2 inhibitors, continue to emerge as valuable additions to treatment regimens.

9. Differential Diagnosis in STEMI: A Comprehensive Overview

Several other conditions can present with ST-segment elevation on an electrocardiogram (ECG), which is characteristic of ST-elevation myocardial infarction (STEMI). These include myocarditis, pericarditis, stress cardiomyopathy (Takotsubo), benign early repolarization, acute vasospasm (Prinzmetal angina), spontaneous coronary artery dissection (SCAD), left bundle branch block (LBBB), various channelopathies, and electrolyte disturbances (Morrow et al., 2000). Understanding these differential diagnoses is critical for accurate clinical assessment and timely treatment of patients presenting with chest pain and potential STEMI (Figure 1).

9.1 Takotsubo Cardiomyopathy

Takotsubo cardiomyopathy, also known as "broken heart syndrome," is a unique cardiac condition that has garnered significant attention in recent years. First described in Japan in the early 1990s, this syndrome is characterized by acute and profound left ventricular dysfunction, typically triggered by intense emotional stress or significant life events. Unlike myocardial infarction, which is primarily due to obstructed coronary arteries, Takotsubo cardiomyopathy occurs in the absence of substantial coronary occlusions (Kubzansky & Kawachi, 2000). The pathophysiology of this condition remains unclear, though it is believed to involve a combination of catecholamine surge and microvascular dysfunction. Patients with Takotsubo experience symptoms similar to those of STEMI, including chest pain and dyspnea, but coronary angiography often reveals no significant coronary artery disease (Nadir & Malik, 2022).

9.2 Prinzmetal Angina (Vasospastic Angina)

Prinzmetal angina, or vasospastic angina (VSA), is a condition characterized by transient, spontaneous coronary artery spasm, which can lead to chest pain and, in severe cases, myocardial infarction. VSA is more likely to occur in individuals with heightened coronary vasoconstriction and diminished vasodilation capabilities. While the exact prevalence of VSA remains unclear, a study conducted in Japan suggests it may affect approximately 40% of individuals with angina, a rate potentially higher than in white populations, possibly due to differences in clinical testing methods (Kimura et al., 2019). The diagnosis of VSA is confirmed through provocative testing with agents such as acetylcholine, and treatment often involves the use of calcium channel blockers and nitrates, along with the management of risk factors like smoking, hypertension, and hyperlipidemia (Beltrame et al., 2017).

9.3 Spontaneous Coronary Artery Dissection (SCAD)

Spontaneous coronary artery dissection (SCAD) is a rare but increasingly recognized cause of acute coronary syndrome (ACS), characterized by the formation of a tear in the coronary artery wall. This condition occurs without prior trauma, medical procedures, or atherosclerosis, distinguishing it from other causes of ACS, such as plaque rupture (Hayes et al., 2018). The pathophysiology of SCAD involves intimal disruption or the creation of an intramural hematoma, which results in coronary artery obstruction. SCAD typically affects younger women and is associated with a lack of traditional cardiovascular risk factors (Solinas et al., 2022). Diagnosis can be challenging, as SCAD often mimics the presentation of atherosclerotic coronary artery disease. Coronary angiography or intravascular imaging, such as optical coherence tomography, is required for definitive diagnosis. While SCAD can lead to severe outcomes, it can often be managed conservatively, and prognosis is generally favorable in the absence of complications such as left ventricular dysfunction or recurrent dissection.

9.4 Prognostic Tools in STEMI

The Thrombolysis in Myocardial Infarction (TIMI) Risk Score is a widely utilized tool that helps clinicians assess the risk of 30-day mortality in patients presenting with STEMI. The TIMI score incorporates several clinical parameters, including age, comorbid conditions such as diabetes and hypertension, systolic blood pressure, heart rate, Killip class, and body weight (Morrow et al., 2000). The score ranges from 0 to 14, with higher scores indicating greater risk. For example, patients over 75 years old receive 3 points, while those aged 64 to 74 receive 2 points. Similarly, a systolic blood pressure lower than 100 mm Hg adds 3 points to the score, while a heart rate above 100 beats per minute adds 2 points. The TIMI score allows for risk stratification, identifying patients at low, medium, or high risk for adverse outcomes. This risk stratification is essential for guiding treatment decisions, including the need for early invasive interventions (Scruth, Cheng, & Worrall-Carter, 2013).

9.5 Mechanical Complications of STEMI

STEMI is associated with three major life-threatening mechanical complications: ventricular free wall rupture, interventricular septum rupture, and acute mitral regurgitation (Kutty, Jones, & Moorjani, 2013). Ventricular free wall rupture is the most common and fatal mechanical complication, with a mortality rate exceeding 80% (Batts, Ackermann, & Edwards, 1990). It typically occurs within five days of the infarction and leads to cardiac tamponade. Early recognition and prompt surgical intervention are crucial for improving survival outcomes in these patients. Similarly, interventricular septum rupture, though less common, also results in significant morbidity and mortality, with a high mortality rate exceeding 70% in patients who do not undergo timely surgical repair (Figueras et al., 2008). Acute mitral regurgitation following STEMI is most commonly caused by ischemic displacement or rupture of the papillary muscle, leading to severe mitral valve insufficiency. In severe cases, it can lead to pulmonary edema and rapid deterioration of the patient's clinical status (Tcheng et al., 1992).

Figure 1. STEMI Equivalents



Figure 2. Myocardial Infarction

9.6 Postcardiac Injury Syndrome

Postcardiac injury syndrome, also known as Dressler syndrome, can occur after a myocardial infarction or cardiac surgery. It is characterized by the development of pericarditis, pericardial effusion, and pleural effusion due to inflammation of the pericardium and pleura. This condition may manifest as chest pain, fever, and malaise, and is usually managed with anti-inflammatory agents such as aspirin or colchicine (Malik et al., 2021). While often self-limiting, postcardiac injury syndrome can complicate recovery and prolong hospitalization. Monitoring for the development of pericardial effusion or cardiac tamponade is important, as these complications can worsen the patient's prognosis.

9.7 Enhancing Healthcare Team Outcomes

One of the key goals in the management of STEMI is achieving door-to-balloon (DTB) time of under 90 minutes. This metric refers to the time interval between a patient's arrival at the emergency department and the successful crossing of the culprit lesion during percutaneous coronary intervention (PCI). A reduction in DTB time has been shown to improve patient outcomes and is considered a core performance indicator for PCI-capable hospitals. Effective teamwork between emergency medical services (EMS), emergency department physicians, and interventional cardiologists is essential for achieving optimal DTB times (Bradley et al., 2009). In 2010, data showed that the median DTB time in the United States was 64 minutes, with 91% of patients receiving PCI within 90 minutes (Krumholz et al., 2011). Continued efforts to reduce DTB times and enhance coordination among healthcare teams will further improve outcomes for patients with STEMI.

STEMI presents a complex clinical picture that requires a comprehensive differential diagnosis. Conditions such as Takotsubo cardiomyopathy, Prinzmetal angina, SCAD, and postcardiac injury syndrome must be considered to avoid misdiagnosis and ensure appropriate management. Tools like the TIMI risk score aid in the early identification of high-risk patients, and awareness of potential mechanical complications can guide timely intervention. By optimizing treatment protocols and enhancing teamwork, healthcare teams can improve the prognosis for STEMI patients and reduce the incidence of complications.

10. Role of Pharmacists, Emergency Providers, and Nursing in the Management of STEMI

The management of ST-segment elevation myocardial infarction (STEMI) requires a multifaceted and coordinated approach, with the involvement of a multidisciplinary team of healthcare professionals. Pharmacists, emergency providers, and nursing staff each play integral roles in ensuring timely, effective care for patients. Their combined efforts in pharmacotherapy, emergency interventions, and continuous monitoring contribute to improving patient outcomes, reducing morbidity and mortality, and optimizing recovery. Effective communication and collaboration among these teams are essential in addressing the diverse and complex needs of patients experiencing STEMI.

10.1 Pharmacists' Role

Pharmacists play a central role in the pharmacotherapeutic management of STEMI, providing expertise in medication selection, dosing, monitoring, and patient education. The timely administration of medications such as antiplatelet agents, anticoagulants, and thrombolytic therapy is crucial to restoring coronary blood flow and reducing myocardial damage in the acute phase of STEMI. Pharmacists are responsible for ensuring that the appropriate drug regimen is selected based on the latest clinical guidelines and individualized to the patient’s clinical condition, comorbidities, and potential contraindications.

One of the key responsibilities of pharmacists in the acute phase of STEMI is the management of antithrombotic therapy. Medications such as aspirin, P2Y12 inhibitors (e.g., clopidogrel, ticagrelor), and heparin or low molecular weight heparin are routinely used to prevent thrombus formation and promote reperfusion in STEMI patients (Alpert et al., 2000). Pharmacists are involved in the careful selection of these drugs, ensuring that they are administered at the correct doses and monitoring for potential drug interactions, especially in patients with multiple comorbidities who may be receiving other medications that could interfere with STEMI treatment.

Furthermore, pharmacists are instrumental in adjusting medications based on patient-specific factors, such as renal and hepatic function, which may influence drug metabolism and elimination (Thygesen et al., 2019). For example, patients with renal impairment may require dose adjustments for anticoagulants, while those with diabetes or hypertension may need adjustments in their antihypertensive regimen to reduce the risk of adverse effects. By individualizing pharmacotherapy, pharmacists help minimize the risk of adverse drug reactions and ensure the optimal therapeutic benefit for the patient.

In addition to medication management, pharmacists provide vital patient education, both in the hospital and after discharge. Educating patients on the proper use of medications, especially for long-term secondary prevention, is critical for reducing the risk of recurrent cardiovascular events (Canto et al., 2011). Statins, antihypertensive drugs, and antiplatelet agents are commonly prescribed after STEMI, and pharmacists ensure that patients understand the importance of adhering to these therapies. They also provide guidance on lifestyle modifications, such as diet and exercise, that can complement pharmacotherapy and improve long-term cardiovascular health (Timmis et al., 2022).

10.2 Emergency Providers' Role

Emergency providers, including paramedics and emergency department (ED) physicians, are often the first healthcare professionals to encounter patients with STEMI. Their prompt and effective interventions are crucial in limiting myocardial damage and improving long-term survival rates. The emergency provider's role in STEMI management begins in the pre-hospital phase, where the rapid recognition of STEMI and initiation of early interventions are key to reducing ischemia and myocardial injury.

Paramedics are trained to identify STEMI based on clinical signs and symptoms, including chest pain, shortness of breath, and electrocardiogram (ECG) changes, particularly ST-segment elevation (Bhatt et al., 2022). Once STEMI is suspected, paramedics play a critical role in notifying the receiving hospital, enabling rapid triage and prioritization of the patient upon arrival. In some cases, they may directly transport the patient to a percutaneous coronary intervention (PCI) center, bypassing the ED to facilitate immediate reperfusion therapy.

The timely transport of STEMI patients to appropriate facilities is essential for ensuring that reperfusion therapy can be administered within the recommended time window. The longer the delay in reperfusion, the greater the extent of myocardial damage, which can lead to worse outcomes (Reimer & Jennings, 1979). Emergency department physicians, once the patient arrives at the hospital, are responsible for confirming the diagnosis of STEMI and assessing the patient's clinical condition. They must quickly determine the most appropriate reperfusion strategy—either thrombolysis or primary PCI—based on the time from symptom onset, the availability of resources, and the patient's clinical stability (Amsterdam et al., 2014).

In addition to managing reperfusion therapy, emergency providers must be vigilant in identifying and managing any complications that may arise during the acute phase of STEMI. Arrhythmias, such as ventricular fibrillation or tachycardia, as well as hemodynamic instability, are common complications that can significantly affect patient survival (Wilson, 1994). Emergency providers' ability to rapidly recognize and treat these complications can dramatically improve patient outcomes.

10.3 Nursing Role

Nurses play an essential role in the comprehensive care of patients with STEMI, providing continuous monitoring, symptom management, and patient education. Their role extends from the moment the patient enters the emergency department through hospitalization and discharge. Nurses are responsible for conducting initial assessments, including vital sign monitoring, ECG analysis, and pain assessment, which are crucial for detecting changes in the patient's clinical condition (Scharf, 2018).

During the acute phase of STEMI, nurses administer medications, including fibrinolytics or anticoagulants, and closely monitor the patient for adverse reactions or bleeding complications. For example, patients receiving fibrinolytic therapy are at risk for bleeding, and nurses must vigilantly monitor for signs of internal bleeding or hemorrhage (Kolodgie et al., 2001). In patients undergoing PCI, nurses are responsible for ensuring that the procedure is performed safely, monitoring the catheter insertion site for signs of bleeding, and providing post-procedure care to minimize complications (McCord et al., 2008).

Nurses also play a critical role in patient education, ensuring that patients understand their diagnosis, treatment plan, and the importance of adherence to prescribed medications after discharge. This education is especially important for preventing readmission and improving long-term cardiovascular outcomes (Glarner et al., 2023). Nurses provide guidance on the signs and symptoms of STEMI, lifestyle modifications, and the proper use of medications such as antiplatelet agents and statins. By empowering patients with the knowledge and tools to manage their health, nurses contribute significantly to improving patient outcomes.

In the post-acute phase, nurses continue to monitor for any signs of complications and coordinate with other healthcare professionals to provide ongoing care. Their involvement in discharge planning is critical for ensuring that patients understand their treatment regimen, follow-up care, and necessary lifestyle changes (Cohen & Visveswaran, 2020). By providing holistic care and support, nurses help improve patients' quality of life and reduce the risk of further cardiovascular events.

The management of STEMI is a complex process that requires the coordinated efforts of pharmacists, emergency providers, and nursing staff. Pharmacists ensure the safe and effective use of medications, including antithrombotic therapy, and provide patient education to support long-term recovery. Emergency providers play a crucial role in the rapid identification and treatment of STEMI, while nurses provide ongoing care, monitor for complications, and educate patients on lifestyle changes and medication adherence. Through collaboration and effective communication, these healthcare professionals work together to improve patient outcomes and reduce the burden of STEMI-related morbidity and mortality.

10.4 Perspective

The management of acute ST-segment elevation myocardial infarction (STEMI) continues to represent one of the most critical challenges in contemporary cardiovascular medicine. Despite advancements in diagnostic tools and treatment modalities, the condition remains a leading cause of morbidity and mortality worldwide. A comprehensive, multidisciplinary approach is paramount, as STEMI management demands rapid and precise actions at every stage of care. Emergency providers, pharmacists, and nurses each bring unique expertise and perspectives, ensuring that all aspects of care are addressed, from initial diagnosis to long-term recovery.

Emergency providers operate at the frontline, tasked with the crucial responsibility of identifying STEMI and initiating life-saving interventions. Their ability to rapidly interpret 12-lead electrocardiograms (ECGs), assess biomarkers, and activate reperfusion protocols is instrumental in minimizing myocardial damage. Pharmacists complement this acute care by optimizing pharmacotherapy, tailoring drug regimens to individual patient profiles, and mitigating risks associated with polypharmacy or comorbid conditions. Nurses, in turn, provide continuous patient monitoring and holistic care, bridging the gap between acute treatment and recovery.

This multidisciplinary collaboration underscores the evolution of STEMI care into a team-based effort that transcends traditional silos. It also highlights the need for ongoing education and training for healthcare professionals to keep pace with emerging evidence and technologies. Furthermore, the integration of patient-centered approaches, including education on lifestyle modifications and adherence to secondary prevention strategies, reinforces the role of the healthcare team in reducing recurrent cardiovascular events.

The lessons drawn from managing STEMI extend beyond the acute setting. They inform broader strategies for addressing other time-sensitive and high-risk conditions, underscoring the value of streamlined workflows, interdisciplinary coordination, and evidence-based practices. In the global context, addressing disparities in access to care—such as limited availability of primary percutaneous coronary intervention (PCI) or fibrinolytic therapy in resource-limited settings—remains an essential priority. Advances in telemedicine, mobile diagnostics, and decentralized healthcare models may offer opportunities to bridge these gaps and extend the reach of effective STEMI care.

11.Conclusion

STEMI management exemplifies the critical importance of a well-coordinated, multidisciplinary approach in acute care. Emergency providers, pharmacists, and nurses each fulfill indispensable roles, from early recognition and rapid intervention to ongoing monitoring and patient education. The integration of their expertise significantly improves survival rates and long-term outcomes for STEMI patients.

However, challenges remain in ensuring equitable access to high-quality care, particularly in underserved regions or systems with limited resources. Continued investment in education, training, and healthcare infrastructure is essential to ensure that life-saving interventions are accessible to all patients, regardless of geographic or socioeconomic barriers.

Looking forward, the evolution of STEMI care will likely be shaped by advancements in diagnostic technologies, novel pharmacological therapies, and innovative care delivery models. Emphasizing collaboration, adaptability, and patient-centered approaches will be critical in meeting these challenges. By fostering a culture of interdisciplinary teamwork and prioritizing evidence-based practices, healthcare systems can optimize outcomes for STEMI patients and set a benchmark for managing other critical health emergencies.

Author contributions

All authors contributed equally to the conceptualization, design, data collection, analysis, and interpretation of the study. S.O.A.A., N.M.M.A., H.M.N.A., S.H.S.A., N.S.A.A., E.S.A., H.A.A., A.M.M.A., W.A.A., Z.Z.A., R.M.A., S.F.A.A., S.S.A., A.A.A., M.N.F.A., and A.A.S.A. actively participated in drafting and revising the manuscript. A.A.S.A. served as the corresponding author, overseeing the coordination and final approval of the manuscript.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Aarvik, M. D., Sandven, I., Dondo, T. B., Gale, C. P., Ruddox, V., Munkhaugen, J., Atar, D., & Otterstad, J. E. (2019). Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: A systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 5(1), 12–20. https://doi.org/10.1093/ehjcvp/pvy034

ACE Inhibitor Myocardial Infarction Collaborative Group. (1998). Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation, 97(22), 2202–2212. https://doi.org/10.1161/01.CIR.97.22.2202

Alpert, J. S., Thygesen, K., Antman, E., & Bassand, J. P. (2000). Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology, 36(3), 959–969.

Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E. Jr., Ganiats, T. G., Holmes, D. R. Jr., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., Levine, G. N., Liebson, P. R., Mukherjee, D., Peterson, E. D., Sabatine, M. S., Smalling, R. W., & Zieman, S. J. (2014). 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 64(24), e139–e228.

Anand, A., Lee, K. K., Chapman, A. R., Ferry, A. V., Adamson, P. D., Strachan, F. E., Berry, C., Findlay, I., Cruikshank, A., Reid, A., Collinson, P. O., Apple, F. S., McAllister, D. A., Maguire, D., Fox, K. A. A., Newby, D. E., Tuck, C., Harkess, R., Keerie, C., Weir, C. J., Parker, R. A., Gray, A., Shah, A. S. V., Mills, N. L., & HiSTORIC Investigators. (2021). High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: A stepped-wedge cluster randomized controlled trial.

Circulation, 143(23), 2214–2224. https://doi.org/10.1161/CIRCULATIONAHA.120.052380

Arbel, Y., Ko, D. T., Yan, A. T., Cantor, W. J., Bagai, A., Koh, M., Eberg, M., Tan, M., Fitchett, D., Borgundvaag, B., Ducas, J., Heffernan, M., Morrison, L. J., Langer, A., Dzavik, V., Mehta, S. R., Goodman, S. G., & TRANSFER-AMI Trial Investigators. (2018). Long-term follow-up of the trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction (TRANSFER-AMI). The Canadian Journal of Cardiology, 34(6), 736–743. https://doi.org/10.1016/j.cjca.2018.02.005

Batts, K. P., Ackermann, D. M., & Edwards, W. D. (1990). Postinfarction rupture of the left ventricular free wall: Clinicopathologic correlates in 100 consecutive autopsy cases. Human Pathology, 21(5), 530–535.

Beltrame, J. F., Crea, F., Kaski, J. C., Ogawa, H., Ong, P., Sechtem, U., Shimokawa, H., Bairey Merz, C. N., & Coronary Vasomotion Disorders International Study Group (COVADIS). (2017). International standardization of diagnostic criteria for vasospastic angina. European Heart Journal, 38(33), 2565–2568. https://doi.org/10.1093/eurheartj/ehv351

Bhatt, D. L., Lopes, R. D., & Harrington, R. A. (2022). Diagnosis and treatment of acute coronary syndromes: A review. JAMA, 327(7), 662–675. https://doi.org/10.1001/jama.2022.0358

Boeddinghaus, J., Nestelberger, T., Lopez-Ayala, P., Koechlin, L., Buechi, M., Miro, O., ... & Mueller, C. (2019). Comparison of fourteen rule-out strategies for acute myocardial infarction. International Journal of Cardiology, 283, 41–47. https://doi.org/10.1016/j.ijcard.2018.11.140

Bradley, E. H., Nallamothu, B. K., Herrin, J., Ting, H. H., Stern, A. F., Nembhard, I. M., Yuan, C. T., Green, J. C., Kline-Rogers, E., Wang, Y., Curtis, J. P., Webster, T. R., Masoudi, F. A., Fonarow, G. C., Brush, J. E. Jr., & Krumholz, H. M. (2009). National efforts to improve door-to-balloon time: Results from the Door-to-Balloon Alliance. Journal of the American College of Cardiology, 54(25), 2423–2429. https://doi.org/10.1016/j.jacc.2009.11.003

Canto, J. G., Kiefe, C. I., Rogers, W. J., Peterson, E. D., Frederick, P. D., French, W. J., Gibson, C. M., Pollack, C. V. Jr., Ornato, J. P., Zalenski, R. J., Penney, J., Tiefenbrunn, A. J., Greenland, P., & NRMI Investigators. (2011). Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA, 306(19), 2120–2127. https://doi.org/10.1001/jama.2011.1654

Cohen, M., & Visveswaran, G. (2020). Defining and managing patients with non-ST-elevation myocardial infarction: Sorting through type 1 vs. other types. Clinical Cardiology, 43(3), 242–250. https://doi.org/10.1002/clc.23308

Crenshaw, B. S., Granger, C. B., Birnbaum, Y., Pieper, K. S., Morris, D. C., Kleiman, N. S., Vahanian, A., Califf, R. M., & Topol, E. J. (2000). Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation, 101(1), 27–32.

Glarner, N., Puelacher, C., Gualandro, D. M., Buse, G. L., Hidvegi, R., Bolliger, D., ... & Mueller, C. (2023). Guideline adherence to statin therapy and association with short-term and long-term cardiac complications following noncardiac surgery: A cohort study. European Journal of Anaesthesiology, 40(11), 854–864.

Hartikainen, T. S., Sörensen, N. A., Haller, P. M., Goßling, A., Lehmacher, J., Zeller, T., ... Neumann, J. T. (2020). Clinical application of the 4th Universal Definition of Myocardial Infarction. European Heart Journal, 41(23), 2209–2216. https://doi.org/10.1093/eurheartj/ehaa035

Hayes, S. N., Kim, E. S. H., Saw, J., Adlam, D., Arslanian-Engoren, C., Economy, K. E., ... Stroke Council. (2018). Spontaneous coronary artery dissection: Current state of the science: A scientific statement from the American Heart Association. Circulation, 137(19), e523–e557. https://doi.org/10.1161/CIR.0000000000000564

Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., ... Zeymer, U. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 39(2), 119–177. https://doi.org/10.1093/eurheartj/ehx393

Khawaja, A. M., Nguyen, E., & Dunning, J. (2021). Sgarbossa criteria for diagnosis of myocardial infarction in patients with left bundle branch block. Journal of Clinical Medicine, 10(10), 2259. https://doi.org/10.3390/jcm10102259

Kolodgie, F. D., Burke, A. P., Farb, A., Gold, H. K., Yuan, J., Narula, J., ... Virmani, R. (2001). The thin-cap fibroatheroma: A type of vulnerable plaque—the major precursor lesion to acute coronary syndromes. Current Opinion in Cardiology, 16(5), 285–292.

Kolodgie, F. D., Virmani, R., Burke, A. P., & Farb, A. (2001). Role of coronary artery disease in myocardial infarction: Implications for acute coronary syndrome diagnosis and treatment. Annals of the New York Academy of Sciences, 946, 7–26. https://doi.org/10.1111/j.1749-6632.2001.tb03745.x

Krumholz, H. M., Herrin, J., Miller, L. E., Drye, E. E., Ling, S. M., Han, L. F., ... Curtis, J. P. (2011). Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation, 124(9), 1038–1045. https://doi.org/10.1161/CIRCULATIONAHA.111.044107

Kubzansky, L. D., & Kawachi, I. (2000). Going to the heart of the matter: Do negative emotions cause coronary heart disease? Journal of Psychosomatic Research, 48(4–5), 323–337.

McCord, J., Jneid, H., Hollander, J. E., de Lemos, J. A., Cercek, B., Hsue, P., ... American Heart Association Acute Cardiac Care Committee. (2008). Management of cocaine-associated chest pain and myocardial infarction: A scientific statement from the American Heart Association. Circulation, 117(14), 1897–1907. https://doi.org/10.1161/CIRCULATIONAHA.107.188950

Morrow, D. A., Antman, E. M., Charlesworth, A., Cairns, R., Murphy, S. A., de Lemos, J. A., ... Braunwald, E. (2000). TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation. Circulation, 102(17), 2031–2037.

Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., ... Stroke Statistics Subcommittee. (2016). Heart Disease and Stroke Statistics–2016 Update: A Report from the American Heart Association. Circulation, 133(4), e38–e360. https://doi.org/10.1161/CIR.0000000000000350

Reimer, K. A., & Jennings, R. B. (1979). Myocardial infarction. In The Heart: Physiology and Metabolism (pp. 1775–1784). Springer.

Reimer, K. A., & Jennings, R. B. (1979). The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Laboratory Investigation, 40(6), 633–644.

Scharf, R. E. (2018). Platelet signaling in primary haemostasis and arterial thrombus formation: Part 1. Hamostaseologie, 38(4), 203–210. https://doi.org/10.1055/s-0038-1675144

Scruth, E. A., Cheng, E., & Worrall-Carter, L. (2013). Risk score comparison of outcomes in patients presenting with ST-elevation myocardial infarction treated with percutaneous coronary intervention. European Journal of Cardiovascular Nursing, 12(4), 330–336. https://doi.org/10.1177/1474515112449412

Sgarbossa, E. B., Pinski, S. L., & Barbagelata, A. (1996). Electrocardiographic diagnosis of acute myocardial infarction in the presence of bundle branch blocks. New England Journal of Medicine, 334(10), 648–653. https://doi.org/10.1056/NEJM199603073341004

Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., & White, H. D. (2012). Third universal definition of myocardial infarction. European Heart Journal, 33(20), 2551–2567. https://doi.org/10.1093/eurheartj/ehs184

Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., & ESC Scientific Document Group. (2018). Fourth universal definition of myocardial infarction. European Heart Journal, 40(3), 237–269. https://doi.org/10.1093/eurheartj/ehy462

Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., & ESC Scientific Document Group. (2019). Fourth universal definition of myocardial infarction. European Heart Journal, 40(3), 237–269. https://doi.org/10.1093/eurheartj/ehy462

Thygesen, K., Morrow, D. A., & Scarborough, R. M. (2019). Universal definition of myocardial infarction: Expert consensus and the fourth universal definition of myocardial infarction. Journal of the American College of Cardiology, 74(18), 2550–2571. https://doi.org/10.1016/j.jacc.2019.09.050

Timmis, A., Vardas, P., Townsend, N., Torbica, A., Katus, H., De Smedt, D., Gale, C. P., Maggioni, A. P., Petersen, S. E., Huculeci, R., Kazakiewicz, D., de Benito Rubio, V., Ignatiuk, B., Raisi-Estabragh, Z., Pawlak, A., Karagiannidis, E., Treskes, R., Gaita, D., Beltrame, J. F., McConnachie, A., Bardinet, I., Graham, I., Flather, M., Elliott, P., Mossialos, E. A., Weidinger, F., Achenbach, S., Atlas Writing Group, & European Society of Cardiology. (2022). European Society of Cardiology: Cardiovascular disease statistics 2021. European Heart Journal, 43(8), 716–799. https://doi.org/10.1093/eurheartj/ehab892

Torpy, J. M., Brown, J., & DynaMed Editorial. (2009). Computed tomography angiography in the diagnosis of coronary artery disease. JAMA, 301(22), 2365. https://doi.org/10.1001/jama.2009.793

Wilson, P. W. (1994). Established risk factors and coronary artery disease: The Framingham Study. American Journal of Hypertension, 7(7 Pt 2), 7S–12S.